DAX24.288 +0,4%Est505.760 +0,3%MSCI World4.343 -0,1%Top 10 Crypto11,75 +5,2%Nas23.308 +1,3%Bitcoin75.160 -0,4%Euro1,1714 ±0,0%Öl60,47 +1,3%Gold4.339 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 DroneShield A2DMAA Tesla A1CX3T Lufthansa 823212 Nike 866993 Allianz 840400 Deutsche Telekom 555750 Bayer BAY001 Siemens Energy ENER6Y Amazon 906866 Deutsche Bank 514000 RENK RENK73 Novo Nordisk A3EU6F Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen schließen in der Gewinnzone -- DAX beendet Freitagshandel im Plus -- BoJ erhöht Zinsen auf höchstes Niveau seit drei Jahrzehnten -- DroneShield, BioNTech, Micron, Rüstungsaktien im Fokus
Top News
UBS-Investmentausblick 2026: AI und Technologie prägen die Märkte 2026 UBS-Investmentausblick 2026: AI und Technologie prägen die Märkte 2026
Top-News der Woche: Diese Themen waren diese Woche wichtig Top-News der Woche: Diese Themen waren diese Woche wichtig
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Johnson Johnson Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
176,50 EUR -1,00 EUR -0,56 %
BMN
207,15 USD +0,67 USD +0,32 %
nachbörslich
BTT
Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.424,46 Mrd. EUR

KGV24,98Div. Rendite3,40%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN853260

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4781601046

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJNJ

Johnson Johnson Aktien News

DatumMeistgelesen
EN, Johnson & JohnsonJohnson & Johnson Backs HRS Registry to Advance Real-World Evidence in PFA
EN, Johnson & JohnsonJohnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
PR NewswireJohnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
Wer­bungJohnson Johnson-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireU.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (la...
EN, Johnson & JohnsonU.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
PR NewswireU.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
PR NewswireUnprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multip...
PR NewswireEarlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
EN, Johnson & JohnsonEarlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
EN, Johnson & JohnsonJohnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
PR NewswireJohnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
EN, Johnson & JohnsonJohnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
PR NewswireJohnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
EN, Johnson & JohnsonNew long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
PR NewswireNew long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
EN, Johnson & JohnsonJohnson & Johnson set to revolutionize the treatment of cancer with the acquisition of Halda Therapeutics
EN, Johnson & JohnsonDARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
PR NewswireDARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
EN, Johnson & JohnsonFDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
PR NewswireFDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
EN, Johnson & JohnsonJohnson & Johnson reinforces its leadership in hematology at ASH 2025 unveiling new paradigm-shifting research
EN, Johnson & JohnsonJohnson & Johnson One Year Data Demonstrate Durable Performance and Safety of the Shockwave Javelin Peripheral IVL Catheter in Late-Breaking Presentation at VIVA 2025
EN, Johnson & JohnsonJohnson & Johnson Confirms Durability of IVL in Complex, Below-the-Knee Anatomy in Late-Breaking Presentation at VIVA 2025
EN, Johnson & JohnsonJohnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS
EN, Johnson & JohnsonJohnson & Johnson submits application to U.S. FDA for STELARA® (ustekinumab) in the treatment of pediatric ulcerative colitis
EN, Johnson & JohnsonJohnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
PR NewswireJohnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
EN, Johnson & JohnsonJohnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare
EN, Johnson & JohnsonNew study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
EN, Johnson & JohnsonJohnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare
PR NewswireNew study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
EN, Johnson & JohnsonTREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years
EN, Johnson & JohnsonIcotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
PR NewswireIcotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
PR NewswireTREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
PR NewswirePublished in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
EN, Johnson & JohnsonPublished in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies
PR NewswireIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
EN, Johnson & JohnsonIcotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
EN, Johnson & JohnsonJohnson & Johnson MedTech Highlights Newest Impella Heart Pump and Long-Term Survival Data at TCT 2025

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.